CERo Therapeutics raises $11.67M in secured debt, pledges core IP as collateral
What's the deal? CERo Therapeutics HoldingsDealroom has a profile for this one. Try Dealroom → has completed a post-IPO debt financing worth up to $11,666,108, backed by SRX GlobalDealroom has a profile for this one. Try Dealroom → as lead and involving Keystone Capital PartnersDealroom has a profile for this one. Try Dealroom →. The deal consolidates existing debt into a new senior secured promissory note while adding up to $6 million in fresh funding.
The details: The consolidated note carries an initial principal of $5,666,108.77 — $2.79 million from SRX and $2.87 million, including accrued interest, from notes originally held by Keystone. SRX committed up to $6 million in further advances, with an initial tranche of $775,665 funded at closing.
Why now? The financing gives CERo near-term liquidity. It plans to use the proceeds to pay outstanding trade payables and for working capital.
What's the endgame? CERo develops CER-T cell therapies, led by its candidate CER-1236. The company pledged all capital stock of its subsidiary and substantially all of that unit's assets — including intellectual property tied to CER-1236 — as collateral.
What could go wrong? The note matures on October 15, 2026, just over a month out, and carries a 10% annual interest rate. The structure also bars CERo from paying dividends or taking on additional debt without lender consent.
The signal: The deal marks a step-up from CERo's previous raise, but it trades scale for risk. By staking its lead clinical asset against short-dated, secured debt, the company signals that immediate liquidity — not favourable terms — is driving its financing strategy.
Read more: minichart.com.sg
Image credit: National Institutes of Health (NIH)
